Gene therapy shot aims to stop diabetic eye disease in its tracks

NCT ID NCT07592273

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 23, 2026 · Updated 8 times

Summary

This study tests a one-time gene therapy called surabgene lomparvovec (Sura-vec) for diabetic retinopathy, a common eye problem from diabetes that can lead to blindness. About 576 adults with moderate-to-severe non-proliferative diabetic retinopathy will receive either the gene therapy or a sham procedure. The goal is to see if the treatment can improve the retina and prevent vision-threatening events over five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: surabgene lomparvovec (Sura-vec)
What this could lead to: If successful, this one-time gene therapy could prevent vision loss and reduce the need for repeated eye injections in people with diabetic retinopathy.
What could go wrong: This is an early-to-mid stage trial with only 576 participants. The therapy involves a novel injection method and requires steroid use, which may cause side effects like inflammation. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

background diabetic retinopathy diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC RETINOPATHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Austin Research Center for Retina /ID# 276101
RECRUITING

Austin, Texas, 78705, United States
California Eye Specialists Medical Group /ID# 274705
RECRUITING

Pasadena, California, 91107, United States
Emanuelli Research & Development Center /ID# 275378
RECRUITING

Arecibo, 00612, Puerto Rico
Florida Retina Consultants - Lakeland /ID# 275012
RECRUITING

Lakeland, Florida, 33805, United States
Macula Retina Vitreous Center - Torrance /ID# 282878
RECRUITING

Torrance, California, 90503, United States
Mid Atlantic Retina Specialists - Hagerstown /ID# 274725
RECRUITING

Hagerstown, Maryland, 21740, United States
Northern California Retina Vitreous Associates /ID# 282994
RECRUITING

Mountain View, California, 94040-4119, United States
Retina Associates Of Cleveland - Beachwood /ID# 275985
RECRUITING

Beachwood, Ohio, 44122, United States
Retinal Consultants Of Arizona - Phoenix - North /ID# 283407
RECRUITING

Phoenix, Arizona, 85053, United States
Sierra Eye Associates /ID# 274737
RECRUITING

Reno, Nevada, 89502, United States
Southwest Retina Research Center /ID# 276094
RECRUITING

Durango, Colorado, 81303, United States
Star Retina /ID# 276513
RECRUITING

Burleson, Texas, 76028, United States
Texas Retina Associates - Dallas /ID# 276117
RECRUITING

Dallas, Texas, 75231, United States
University Retina - Oak Forest /ID# 283021
RECRUITING

Oak Forest, Illinois, 60452, United States
Vistar Eye Center - Salem /ID# 282879
RECRUITING

Salem, Virginia, 24153, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.